Trial Profile
A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP33337)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Planned End Date changed from 31 Mar 2019 to 30 Jun 2019.
- 22 Nov 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.